Corbus Pharmaceuticals Holdings Inc

Corbus insiders’ RSU and option awards signal strong confidence as the company heads into key clinical milestones; investors should watch potential dilution and upside.

Explore Corbus Pharma’s latest insider trades—sell‑to‑cover RSU sales and big option buys—revealing exec confidence, liquidity, and future upside potential.

Corbus Pharma’s recent insider sales are routine sell‑to‑cover moves, not a sign of declining confidence—yet executive outflows may still prompt investor caution.

Corbus Pharmaceuticals’ COO sells 2,415 shares in a routine “sell‑to‑cover” trade, leaving his stake at 51,927 shares – a modest move that signals confidence, not panic, for investors.